Abelacimab, formerly known as MAA868, represents a novel approach to preventing thrombosis. This antiplatelet agent is a specific monoclonal immunoglobulin that blocks the integrin αIIbβ3, a key player in platelet https://www.targetmol.com/compound/abelacimab